Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate

Savannah F. Bifulco,[1] Griffin D. Scott,[1] Sakher Sarairah,[2] Zeinab Birjandian,[2,5]

Caroline H. Roney,[3] Steven A. Niederer,[3] Christian Mahnkopf,[4] Peter Kuhnlein,[4]

Marcel Mitlacher,[4] David Tirschwell,[5] W. T. Longstreth Jr,[5,6]

Nazem Akoum,[2] Patrick M. Boyle[1,7,8*]*

1: Department of Bioengineering, University of Washington, Seattle, WA, USA.
2: Division of Cardiology, University of Washington, Seattle, WA, USA.
3: School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
4: Department of Cardiology, Klinikum Coburg, Coburg, Germany.
5: Department of Neurology, University of Washington, Seattle, WA, USA.
6: Department of Epidemiology, University of Washington, Seattle, WA, USA.
7: Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
8: Center for Cardiovascular Biology, University of Washington, Seattle, WA, USA.

***: Corresponding authors:**

PM Boyle; email: pmjboyle@uw.edu; mail: Foege N310H UW Mailbox 355061, Seattle WA 98195, USA;
OR,
N Akoum; email: nakoum@cardiology.washington.edu; mail: 1959 N Pacific St, Seattle WA 98115, USA

Word count (main text): 6404

Abstract

Cardiac magnetic resonance imaging (MRI) has revealed fibrosis in embolic stroke of undetermined source (ESUS) patients comparable to levels seen in atrial fibrillation (AFib). We used computational modeling to understand the absence of arrhythmia in ESUS despite the presence of putatively pro-arrhythmic fibrosis. MRI-based atrial models were reconstructed for 45 ESUS and 45 AFib patients. The fibrotic substrate's arrhythmogenic capacity in each patient was assessed computationally. Reentrant drivers were induced in 24/45 (53%) ESUS and 22/45 (49%) AFib models. Inducible models had more fibrosis (16.7±5.45%) than non-inducible models (11.07±3.61%; P<0.0001); however, inducible subsets of ESUS and AFib models had similar fibrosis levels (P=0.90), meaning the *intrinsic pro-arrhythmic substrate properties* of fibrosis in ESUS and AFib are indistinguishable. This suggests some ESUS patients have latent pre-clinical fibrotic substrate that could be a future source of arrhythmogenicity. Thus, our work prompts the hypothesis that ESUS patients with fibrotic atria are spared from AFib due to an absence of arrhythmia triggers.

Introduction

Atrial fibrillation (AFib) is the most common cardiac arrhythmia, affecting 1-2% of the world's population and significantly contributing to worldwide morbidity and mortality (1). The primary source of AFib-related mortality is stroke, with around 20% of all ischemic strokes occurring in AFib patients (1). Sub-clinical AFib (i.e., transient, asymptomatic AFib) is implicated as a potential cause of embolic stroke of undetermined source (ESUS), and the current course of clinical care following ESUS is to look for evidence of AFib via an external monitor, an implanted loop recorder, or other forms of wearable monitoring devices. If AFib is diagnosed, treatment with oral anticoagulants is started to mitigate the possibility of recurrent stroke (2). Clinical studies have shown that AFib has been detected in only 30% of patients with long-term rhythm monitoring (3). This creates a frustrating problem for clinicians: in the wake of ESUS events, it is impossible to know which individuals should be treated as high-risk for AFib and therefore monitored accordingly.

Recent evidence from clinical studies suggests that the left atrial fibrosis burden measured by late gadolinium enhanced (LGE)-MRI is as high in ESUS patients as in AFib patients without stroke (4). This finding supports the hypothesis that atrial fibrosis is an element of the causal pathway for stroke, through an atrial cardiopathy, and independent of AFib. The absence of AFib despite the presence of a fibrotic substrate is intriguing and one potential explanation is that ESUS patients have pro-arrhythmic fibrotic substrate but lack the triggers needed to initiate arrhythmia. Another potential explanation is that the fibrosis present in ESUS patients is not pro-arrhythmic. Patient-derived computational modeling of atrial arrhythmias is uniquely poised to test these hypotheses. Previously, personalized atrial models have been used to assess arrhythmogenic propensity of fibrotic substrate and predict AFib ablation targets (5, 6). Applying the same approach, we can use computational models to predict if, in the presence of appropriate triggers, fibrotic remodeling in ESUS has the fundamental capacity to harbor reentrant arrhythmic activity.

Thus, we present a large-scale computational study to ascertain whether the fibrotic substrate with the potential to perpetuate AFib-sustaining reentrant drivers (RDs) exists in ESUS. Our hypothesis is that a pre-clinical AFib substrate, attributed to a pattern of fibrotic atrial remodeling that is conducive to RD perpetuation, exists in ESUS patients. By conducting simulations in models derived from LGE-MRI, we can begin to understand potential pro-arrhythmic properties of atrial fibrosis in ESUS patients. The study thus provides insights on the role of atrial fibrosis as a pathophysiological nexus between AFib and stroke.

Results

Patient Characteristics

Ninety patient-derived models were included in our analysis: 45 post-stroke ESUS and 45 pre-ablation AFib patients. Demographic information about both patient groups is provided in **Table 1**. There was a significant difference in LA surface area; however, the potential importance

of this feature for interpreting our findings is offset by the lack of difference in LA volume index (a more commonly used measurement of normalized LA surface area), which suggests higher LA surface area in those with AFib is a consequence of higher body mass index (BMI). LA fibrosis burden was not significantly different between ESUS (13.6 ± 6.2%) and AFib patients (14.2 ± 4.5%) (P=0.91), consistent with previous findings (4).

Table 1. *Patient characteristics in ESUS and AFib groups.*

	ESUS (N=45)	**AFib (N=45)**	**P value**
Age, y	60±16	62±12	0.504
Female, %	44.0%	32.8%	0.275
BMI, kg/m^2	27.6±4.3	29.5±5.9	0.08
CHA_2DVASc score	2.0	1.9	0.345
CHF, n	14.3%	18.4%	0.599
Hypertension, n	68.5%	61.2%	0.468
Diabetes mellitus, n	20.4%	12.2%	0.292
CAD, n	18.4%	18.4%	1.000
Smoking, n	32%	28%	0.679
LA fibrosis, %	13.6±6.2%	14.2±4.5%	0.91
LA surface area, cm^2	109±26	134±40	0.0007
LA volume index, mL/m^2	60±29	57±26	0.607

Induction of arrhythmia and fibrosis quantification in patient-derived models

Personalized LA bilayer models were generated for all ESUS and AFib patients. Examples of physiological detail incorporated in models can be seen in **Fig. 1**, including patient-specific patterns of fibrotic remodeling, realistic atrial fiber orientations, and locations of electric pacing sites; further detail can be found in the Methods section. Rapid electric stimulation caused RD-sustained arrhythmia in 22 of 45 AFib models (48.8%) and 24 of 45 ESUS models (53.3%). Thus, the capability of the fibrotic substrate to sustain RDs was not significantly different between the two groups (P=0.83, **Fig. 2A**). ESUS and AFib models were then sorted by amount of global LA fibrosis and arranged into quartiles. For five models (21.7%) in the first quartile (fibrosis<9.75%), six models (28.5%) in the second quartile (fibrosis<12.6%), 15 (62.5%) models in the third quartile (fibrosis<17. 5%), and 20 (91.0%) models in the top quartile, simulations revealed at least one pacing site for which stimulation produced an episode of RD-sustained arrhythmia (**Fig. 2B**).



Figure 1: *Model generation (A) Reconstruction of LA geometry with anatomical features labelled (RIPV/RSPV/LIPV/LSPV, right/left inferior/superior pulmonary veins; LAA, LA appendage). The LA is modeled as a bilayer comprising nested endocardial and epicardial shells linked in both fibrotic and non-fibrotic regions by 1D linear elements. (B) LA fiber orientations for the endocardium and epicardium, mapped from human atlas geometry as described in Methods. (C) AFib trigger sites as pacing sites (posterior/anterior LIPV, LSPV, RSPV, RIPV, LAA base, mitral valve annulus and posterior wall). (D) Regions of the LA generated as described in methods: (1) atrial floor, (2) anterior wall and LAA, (3) posterior wall, (4) left PVs, (5) right PVs.*



Figure 2: *Summary of patient-derived model fibrosis with respect to RD inducibility. (A) Histogram of AFib (22/45) and ESUS (24/45) inducible patients. Inducibility was not significantly different by χ^2 test. (B) Patients with ESUS and AFib arranged by percentage of LA fibrosis. Dotted lines indicate the quartiles of fibrosis observed for all 90 patient-derived models. Circles are indicative of stable reentry observed in the model from at least one pacing site after in silico pacing protocol. Triangles indicate no RDs after pacing from all 15 pacing sites independently. Cases that lacked RDs despite high fibrosis (inset I) or were inducible despite low fibrosis (inset II) are highlighted.*

To explore potential pro-arrhythmic substrate properties in ESUS and AFib, we analyzed fibrosis burden in the sub-groups of each cohort in which RD-sustained arrhythmias were

113 inducible and non-inducible (**Fig. 3A**). Fibrosis burden was not significantly different between
114 inducible ESUS and AFib models with (**Fig. 3A**; P=0.90, confidence interval; CI: [-3.4, 4.1]) or
115 without induced reentry (**Fig. 3A**; P=1, CI: [-2.1, 2.4]). However, when fibrosis burdens for
116 inducible and non-inducible models were aggregated across ESUS and AFib groups, a significant
117 difference was evident (**Fig. 3A**; 16.7 ± 5.46% vs. 11.07 ± 3.61%; P<0.0001, CI: [3.4, 7.6]).

118 We also investigated potential differences in the number of unique RDs and the number
119 of AFib triggers that induced reentry in each patient-derived model. In all 46 inducible models, the
120 median number of unique RDs was 1 for both AFib and ESUS models (AFib range: 1-5; ESUS
121 range: 1-8). There was no significant difference in the number of unique reentrant morphologies
122 per model between the two groups (**Fig. 3B**; P=0.83, CI: [-7.7×10^{-5}, 8.8×10^{-5}]). The number of
123 unique RDs was positively correlated with atrial fibrosis burden (**Fig. 3C**; R=0.63, P<0.0001). For
124 all RD-inducible cases, the median number of stimulation sites from which rapid pacing led to RD
125 formation was 2 for AFib and 3 for ESUS models (range for both groups: 1-9). No significant
126 difference was found in the number of pacing sites that induced reentry per model between AFib
127 and ESUS (**Fig. 3D**; P=0.79, CI [-2.0,1.0]). The number of RD inducing pacing sites was also
128 significantly correlated with fibrosis burden (**Fig. 3E**; R=0.62, P<0.0001).



129

130 **Figure 3:** Summary of RD characteristics between ESUS and AFib models. (A) Boxplot of fibrosis
131 percentage in ESUS and AFib models where reentry was induced (ESUS: N=24, IQR=10.6; AFib: N=22,

IQR=5) and where reentry was not induced (ESUS: N=21, IQR=5; AFib N=23, IQR=3.5). Across ESUS and AFib models, fibrosis burden for RD inducible and RD non-inducible models was significantly different (P<0.0001). (B) Boxplot of number of unique reentrant morphologies elicited by all 15 pacing sites (P=0.83). (C) Correlation plot of fibrosis vs number of RDs (R=0.63, P<0.0001). (D) Boxplot of the number of pacing sites which induced reentry (P=0.79). (E) Correlation plot of fibrosis vs number of pacing sites that induced reentry (R=0.62, P<0.0001).

Arrhythmia Dynamics

Analysis of simulated reentry episodes revealed no qualitative differences in arrhythmia dynamics between AFib and ESUS models. **Figure 4** shows examples of RD-perpetuated *in silico* arrhythmia and instances where stimulation failed to induce reentry for both groups. Of note, this figure highlights two inducible low-fibrosis ESUS models (**Fig. 4A**: 6.9% fibrosis, RD near the LIPV; **Fig. 4B**: 10.0% fibrosis, RD on the atrial floor) and a non-inducible high-fibrosis ESUS model (**Fig. 4C**: 16% fibrosis). In the latter case, dense fibrosis on the posterior wall resulted in conduction block as indicated.



Figure 4: Maps of fibrotic tissue distribution (left) and activation time (right) for ESUS and AFib models in which pacing succeeded (rows 1-2) or failed (row 3) to induce RD-driven arrhythmia. Black arrows indicate

149 directions of wavefront propagation in RDs. Double lines indicate sites of conduction block. Black-shaded
150 regions in activation maps indicate locations where activation did not occur during the analysis interval. (A)
151 ESUS model with 6.9% fibrosis and reentry inferior to LIPV. (B) ESUS model with 10.0% fibrosis and reentry
152 on the atrial floor. (C) ESUS model with 16% fibrosis with wavefront termination through fibrosis on posterior
153 wall. (D) AFib model with 9.9% fibrosis and reentry observed adjacent to RIPV on posterior wall. (E) AFib
154 model with 13.7% fibrosis and reentry observed on the anterior wall. (F) AFib model with 11.6% fibrosis
155 with wavefront collision on posterior wall.

156 **Figures 4D-E** present examples of RD-driven arrhythmia in AFib models (9.9% and 13.7%
157 fibrosis, respectively), and **Fig. 4F** shows an AFib model (11.6% fibrosis) in which reentry was not
158 induced due to wavefront collision in the posterior wall region. Overall, this shows that both ESUS
159 and AFib models exhibited activation patterns consistent with previous definitions of RD-driven
160 arrhythmia; examples of inducible low-fibrosis and non-inducible high-fibrosis models emphasize
161 that fibrosis burden alone is an insufficient predictor for a potential arrhythmic substrate.

162 **Properties of RD Localization**

163 As described in Methods, each model was automatically subdivided into five anatomical
164 regions (see schematic illustrations in **Fig. 1D** and **Supplementary Fig. 1**) and region-wise
165 inducibility score analysis (IdS, as described in Methods) was used to gauge likelihood of RD
166 induction in response to rapid electrical stimulation from different locations in the LA. While ESUS
167 and AFib models had a statistically similar pattern of inducibility rates ($P=0.45$, by χ^2 test),
168 stimulation from the posterior wall was ≈2 times more likely to induce RDs in AFib models than
169 ESUS models (**Fig. 5A**, IdS = 6 vs IdS = 3). In other words, with all other factors held equal, our
170 simulations suggest that triggered activity in the posterior wall may be more likely to initiate
171 reentrant arrhythmia in AFib patients compared to ESUS patients. The same IdS values plotted
172 in **Fig. 5A** were mapped onto representative LA models to facilitate visual comparison of regional
173 sensitivity to rapid pacing (**Fig. 5B**). Next, we considered the number of unique RD localization
174 sites in each LA region across the different model groups (i.e., AFib vs. ESUS). The LPV region
175 was most likely to harbor RDs in the AFib cohort (**Fig. 5C**, N=17). In the ESUS cohort, the atrial

floor was the most likely region to contain an RD (**Fig. 5D**, N=16) The association between the type of model (ESUS vs AFib) and RD localization was not significant (P=0.13, χ^2 test).



Figure 5: Summary of IdS and RD localization characteristics. (A) Region-wise IdS for both ESUS and AFib LA models (B) Heat map of the regions in which triggers are most likely to induce arrhythmias depicted as representative ESUS and AFib models. (C) Histogram of RDs across all AFib and ESUS models binned by localization to specific LA regions. (D) Heat map of regions in which RDs are most likely to localize depicted as representative ESUS and AFib models.

184 In addition to its role as part of the substrate for reentrant arrhythmia, fibrosis may directly
185 lead to increased AFib trigger incidence via calcium dysregulation leading to localized to regions
186 of depolarized resting potential (7, 8). To investigate whether cohort-scale differences in this
187 intrinsic pro-trigger property of fibrosis may explain the lack of arrhythmia in ESUS, we ran
188 additional simulations to assess the total extent of abnormally depolarized tissue (see Methods
189 for definition) in ESUS and AFib models; notably, these values are distinct from total fibrosis
190 burdens, since non-fibrotic tissue can be pulled to a more positive resting potential via electrotonic
191 coupling. We found no significant difference in these values between ESUS and AFib models
192 (P=0.32; CI: [–0.007, 0.019]; **Supplemental Fig. 2**); if anything, there was a trend towards *more*
193 trigger-prone tissue in ESUS. These findings provide preliminary evidence against the notion that
194 the lack of arrhythmia in ESUS might be due to lower rates of fibrosis-related ectopic pacemaking.



195

196 **Figure 6:** Summary of the region-by-region extent of tissue with a spatial fibrosis pattern (as characterized
197 by local density and entropy) associated with RD localization (i.e., pro-RD tissue). (A) Maps of pro-RD
198 tissue for representative AFib and ESUS cases, including boundaries between regions. (B) Region-wise
199 extent of pro-RD tissue in inducible AFib and ESUS models, depicted as boxplots (**: P < 0.01, Wilcoxon
200 rank sum test; CI: [–0.149, –0.021]).

201

202 **Properties of pro-RD Fibrosis**

203 To further examine trends in RD inducibility and localization observed in **Fig. 5**, we also
204 carried out region-wise analysis of fibrosis spatial pattern. In a previous study (5), we used

205 machine learning to quantitatively characterize the fibrosis distribution in regions that most
206 frequently harbored RD organizing centers (i.e., high local fibrosis density *and* entropy). As
207 described in Methods, the distribution of pro-RD tissue regions was determined for each inducible
208 model; these values were then subdivided in the five-region schematic (**Fig. 6A**). This analysis
209 revealed that the extent of pro-RD tissue in the LPV region was significantly higher in AFib
210 compared to ESUS models (**Fig. 6B**; P=0.01); this was consistent with our findings on regional
211 inducibility, and RD localization as shown in **Fig. 5**. Likewise, for regions that were associated
212 with greater inducibility and RD localization in ESUS models (anterior wall + LAA, atrial floor) there
213 was a trend towards a larger extent of pro-RD tissue compared to AFib models, but these did not
214 reach the level of significance.

215

216 Discussion

217 This study used a novel computational modeling approach with stimulus locations chosen
218 based on clinically observed AFib triggers to shed new light on the role of the fibrotic atrial
219 substrate in the potential for initiation and perpetuation of reentry in ESUS patients. In models
220 reconstructed from 45 post-stroke ESUS and 45 pre-ablation AFib patients, we showed that the
221 AFib and ESUS groups did not differ significantly in: (i) the propensity of the fibrotic substrate to
222 sustain RDs in response to simulated burst pacing; (ii) the LA fibrotic burden of RD-inducible
223 models or RD-free models; and (iii) the reentrant driver localization or the region-wise inducibility.
224 One noteworthy difference was that the extent of tissue in the LPV region with a pro-RD fibrosis
225 spatial pattern was greater in AFib vs. ESUS models. This is the first study to use computational
226 modeling and simulation to assess potential pro-arrhythmic capacity of LA fibrosis in ESUS
227 patients. Moreover, to the best of our knowledge, this is the largest cohort ever studied via
228 computational analysis of atrial electrophysiology in models derived from LGE-MRI, exceeding
229 the number of patient-specific models (N=50) in the former largest study (9) by a factor of ≈1.8.

230 **Inducibility of reentry and fibrosis quantification in patient-derived atrial models**

231 Experimental findings have shown that atrial fibrosis results in changes that promote
232 reentry (10, 11), but the exact mechanism of this connection is not fully understood. Previous
233 modeling studies have linked RD localization to specific spatial patterns of fibrotic remodeling in
234 AFib (5, 12). Recent clinical findings indicate that atrial fibrosis burden does not differ significantly
235 between AFib and ESUS patients, and yet (by definition) ESUS patients do not demonstrate AFib
236 at the time of stroke or during ambulatory monitoring (4). Given the findings summarized above,
237 a potential explanation is that, notwithstanding the fact that ESUS patients have substantial
238 fibrosis, the particular *spatial distribution* of fibrotic remodeling in their atria is not conducive to
239 arrhythmia perpetuation. Our findings suggest that this is likely not the case. From the standpoint
240 of computational models derived from patient LGE-MRI scans, fibrotic substrate in individuals with
241 ESUS is indistinguishable from that in patients with AFib in terms of the fundamental capacity to
242 sustain RDs. For inducible models from both cohorts, we found that high fibrosis models were
243 more likely to exhibit RDs irrespective of whether they corresponded to ESUS or AFib patients.
244 This is in agreement with prior computational studies, which found the same general association
245 (5, 6), and is consistent with clinical understanding, wherein higher fibrosis burden is associated
246 with poor outcomes in AFib ablation procedures (13). Notably, we did observe several cases in
247 which models defied inducibility expectations based on fibrosis alone. Such models exhibited RDs
248 despite low fibrosis or were non-inducible despite high fibrosis. This observation confirms that, as
249 observed previously in analogous AFib modeling studies (5, 6), assessment of raw fibrosis burden
250 LGE-MRI scans alone is insufficient to fully characterize arrhythmogenic capacity of potentially
251 pro-arrhythmic substrate in ESUS. In the present study, this is confirmed by our region-wise
252 analysis of fibrosis spatial pattern (i.e., density, entropy), which is discussed below.

253 Consistent with the goal of this research to understand the contribution of fibrotic substrate
254 to potential RD formation in ESUS, we purposefully excluded arrhythmias perpetuated by other

255 mechanisms from our study design (e.g., self-sustaining activity driven solely by focal sources).
256 This allows us to study the fibrotic substrate in the absence of all other confounding factors.
257 Additionally, our analysis of abnormal steady-state depolarization in LA models suggests the
258 potential for fibrosis itself to serves as a source of arrhythmia triggers is no greater in AFib than
259 in ESUS models. Potential contributions from the right atrium (RA) were also excluded, since only
260 the LA was segmented from LGE-MRI as part of the clinical workflow. Either of these factors may
261 explain the absence of simulated arrhythmia in 23 of 45 AFib models, many of which had very
262 little LA fibrosis (i.e., AFib in these individuals might have been predominantly focal in nature or
263 sustained by RDs in the RA). This rate of inducibility is consistent with previous studies (e.g.,13
264 out of 20 in computational models reconstructed from LGE-MRI scans of persistent AFib patients)
265 (5), supporting the notion that LA fibrosis is associated with increased arrhythmia inducibility but
266 fails to tell the whole story. Importantly, neither of these model constraints repudiates the central
267 finding of our study, which suggests there is no difference between ESUS and AFib patients in
268 terms of the fundamental capacity of the fibrotic substrate to potentially harbor RDs.

269 **Reentrant driver localization dynamics and morphology in patient-derived atrial models**

270 As discussed above, our qualitative findings suggest that ESUS patients' fibrotic substrate
271 is no different than that of AFib patients in terms the capacity to sustain RDs per se. We performed
272 additional analysis to assess whether specific consequences of fibrotic remodeling influenced any
273 characteristics of RD inducibility in different ways for simulations in models corresponding to
274 ESUS vs. AFib patients. First, we found that there was no significant difference in global fibrosis
275 burden between inducible AFib and ESUS models. Thus, our computational modeling suggests
276 that intrinsic pro-arrhythmic traits of ESUS and AFib fibrotic substrate are indistinguishable. Given
277 this result, one potential alternative explanation for the lack of arrhythmia in ESUS patients is a
278 lack of suitable triggers, despite an abundance of fibrotic substrate on par with that observed in
279 AFib. The plausibility of this explanation is strengthened by the fact that the pacing sites from
280 which episodes of reentry were induced in our study were based on common AFib trigger sites

281 as identified in a recent clinical study (14); this is in contrast to previous modeling studies, which
282 simulated triggered activity from evenly-distributed atrial sites (6). Nevertheless, the premise of
283 this aspect of our work was not to assess an absence of triggers, but instead ask the following: if
284 the atria of these ESUS patients were subjected to the same type of triggered activity known to
285 occur in typical AFib patients, is it possible the result be would sustained arrhythmia? In more
286 than half of the cohort (24/45), our analysis suggests that the answer is yes. This new hypothesis
287 could be validated in future studies by designing clinical protocols that systematically monitor
288 ESUS patients with different levels of fibrosis for potential AFib triggers via electrocardiographic
289 readouts.

290 Further analysis was performed to probe potential differences between ESUS and AFib
291 simulations that went beyond consideration of RD inducibility as a binary variable. Specifically,
292 we found no difference in the number of unique model-predicted RDs or the number of pacing
293 sites that induced RDs between ESUS and AFib. Instead, these variables were highly correlated
294 with LA fibrosis burden, which is consistent with the concept that high fibrosis models are more
295 susceptible to pacing-induced RDs. This finding further substantiates our principal claim that no
296 significant differences exist between the detected fibrotic substrate in ESUS and AFib, in that it
297 holds true for the substrate's capacity to sustain reentry and its susceptibility to triggered activity.
298 The general implication is that in the presence of simulated triggered activity, both of these
299 characteristics are closely linked to global fibrosis burden.

300 RDs identified by non-invasive electrocardiographic imaging (ECGI) and *in silico* phase
301 singularity identification have been shown to co-localize with fibrosis boundary zones identified
302 by LGE-MRI (5, 15-17). RD localization dynamics in this study were consistent with these findings,
303 as illustrated by representative LA fibrotic tissue distributions and corresponding RDs in **Fig. 4**.
304 RD morphology in this study corroborated previous findings – arrhythmias were perpetuated by
305 one RD at a time, with activity in the periphery including conduction block, transient reentry, and
306 wavefront collision (5, 6).

307 **Insights from analysis of RD inducibility and localization by LA region**

308 Further to the macroscopic analysis discussed above, our region-by-region analysis of RD
309 inducibility and localization showed that spatial properties of the fibrotic substrate between AFib
310 and ESUS models are not intrinsically different. However, this analysis yielded several noteworthy
311 findings that suggest subtle distinctions in fibrosis pattern may exist between the two groups. The
312 most striking difference exists for the posterior wall region, where the IdS score was ≈2x higher
313 in AFib compared to ESUS models. Thus, even in cases where posterior LA wall ectopic
314 excitations occur in ESUS patients, our simulations suggest that they could be up to 50% less
315 likely to engage the fibrotic substrate and initiate sustained reentry compared to the same activity
316 in AFib patients. This possibility does not contradict our hypothesis that the lack of arrhythmia in
317 ESUS is due to a dearth of triggers; rather, it is a complementary corollary that can be put to the
318 test in future clinical and computational analysis.

319 While understanding of RD localization dynamics in AFib remains limited, evidence from
320 ECGI mapping indicates that reentrant activity occurs most frequently in the PV and posterior wall
321 regions (16, 18, 19). Our findings are consistent with these data for AFib but not ESUS models.
322 Many (41.1%) AFib model RDs localized to the LPV region. In contrast, in the ESUS population
323 the RD localization hotspot was the region comprising the anterior wall and LAA (37%). The
324 importance of this finding is unclear, as tendencies toward reentrant activity in particular LA areas
325 have not been meaningfully correlated to clinical arrhythmia properties and are potentially subject
326 to changes in conduction velocity or action potential duration (20). However, it provides a path for
327 future validation studies: if incident AFib in patients who previously presented with ESUS can be
328 characterized by intracardiac mapping, the hypothesis that RDs localize preferentially to the
329 anterior wall can be tested.

330 Finally, our analysis of fibrosis spatial patterns revealed that the proportion of tissue with
331 the propensity to harbor RDs (as established via machine learning in prior work (5)) was higher
332 in the LPV region for AFib compared to ESUS models. While we acknowledge that a more fulsome

333 analysis will be required to draw comprehensive conclusions on this subject, we note that our
334 results are consistent with the most prominent observed regional variabilities in RD localization
335 and inducibility between the two model groups. In contrast, ESUS patients trended toward a
336 higher percentage of pro-RD tissue in all anatomical areas except the LPVs. Thus, despite some
337 interesting and potentially consequential differences in regional distribution of potentially pro-
338 arrhythmic fibrosis, our overarching conclusion remains unchanged: our models suggest that if
339 the ESUS substrate were subjected to suitable triggered activity, it could sustain the same types
340 of RDs as those that contribute to AFib perpetuation.

341 **Limitations**

342 In this study, atrial tissue is modeled as a bilayer to drastically reduce computational load.
343 Previous studies have used this modeling framework (15, 21) to represent human atria effectively,
344 but the framework remains a simplification compared to volumetric 3D models. Moreover, clinical-
345 grade MRI resolution limits our ability to detect fine details in anatomical structure and spatial
346 distribution of potentially arrhythmogenic substrate, for instance slow-conducting tracks of fibrotic
347 atrial tissue that could underlie microreentrant circuits (22). While these models are patient-
348 specific in terms of LA anatomy and each individual's unique pattern of fibrotic remodeling, they
349 do not incorporate inter-patient variability in CV and electrophysiological properties such as ion
350 channel expression. Nevertheless, our previous analysis indicates that this representation of atrial
351 architecture with generic "average AFib" electrophysiology is appropriate for use in patient-
352 derived modeling (12, 20).

353 As in previous studies (23, 24), our models do not differentiate between cell- or tissue-
354 scale properties of atrial electrophysiology between patients with paroxysmal and persistent forms
355 of AFib. Likewise, our approach to characterizing potential arrhythmia propensity in ESUS
356 patients assumes cell- and tissue-scale remodeling based on experimental and clinical data from
357 the AFib milieu. Although this is relevant as a limitation and must be considered when interpreting
358 our results, this aspect of our approach is also one of the major advantages of the modeling and

359 simulation methodology. Specifically, it allows us to assess whether there are any relevant
360 differences in the spatial pattern of fibrotic remodeling between ESUS and AFib patients in the
361 absence of other potentially confounding variables. A related limitation is that patients with stroke
362 were excluded from the AFib cohort. This was because stroke etiology in the database from which
363 AFib patients were drawn was not explicitly adjudicated to be cardioembolic, other ischemic such
364 as atherosclerotic, or hemorrhagic. Therefore, we would not be able to draw reliable conclusions
365 regarding the role of fibrosis in stroke in this population.

366 Finally, the mechanism of stroke in ESUS patients may be independent of AFib.
367 Decreased atrial function due to atrial fibrosis may contribute to reduced hemodynamic efficacy
368 and thrombus formation in the absence of AFib. Currently, secondary stroke prophylaxis is
369 dependent on detecting AFib and predicting, through computational modeling, which atria are
370 more prone to manifest AFib may be of clinical value. Another future research direction that could
371 prove highly fruitful would be to create multi-scale, multi-physics image-based models of the
372 fibrotic atria to assess each individual's risk of clot formation in a patient-specific manner (25).

373

374 Conclusions

375 Simulations suggest that the pro-arrhythmic properties of fibrotic substrate in ESUS and
376 AFib patients are indistinguishable. Our results show that fibrotic remodeling in ESUS patients
377 has the theoretical capacity to sustain reentry when subjected to common AFib triggers. Thus, we
378 conclude that fibrotic substrate conducive to perpetuating reentry may exist in up to half of ESUS
379 patients. As individuals studied in this cohort present with incident AFib over the next few years,
380 we will be able to put this hypothesis to the test. Our findings also support the notion that the lack
381 of AFib in this population may be attributable to a lack of suitable arrhythmic triggers, but further
382 research is needed to fully justify this claim. While the existence of pre-clinical substrate is
383 correlated with a higher global proportion of fibrotic tissue, many ESUS cases defied these

384 expectations, suggesting that fibrosis burden alone is insufficient for predicting pre-clinical AFib
385 substrate. This conclusion justifies the use of computational simulations to probe beyond the
386 fibrosis as imaged. Overall, these results provide novel insights into the role of atrial fibrotic
387 remodeling as a critical nexus between the otherwise distinct manifestations of AFib and ESUS.
388

389 # Methods

390 **Patient Population**

391 Patients were recruited to undergo cardiac LGE-MRI from the University of Washington
392 (Seattle, WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. This
393 study was approved by the Institutional Review Board (IRB) of the University of Washington (UW)
394 and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland;
395 all participants provided written informed consent. Patients with ESUS met published diagnostic
396 criteria (26). Patients with paroxysmal (27/45, 60%) or persistent AFib and without stroke were
397 recruited from the UW Cardiac Arrhythmia Data Repository, an IRB-approved database for
398 arrhythmia patients. Exclusion criteria for AFib patients included those who had undergone LA
399 catheter ablation before MRI and those with only atrial flutter. Patients with cardiac implantable
400 electronic devices, severe claustrophobia, renal dysfunction, and other contraindications to MRI
401 or gadolinium-based contrast were excluded.

402 **MRI acquisition**

403 Cardiac LGE-MRI was obtained on all participants to quantify the extent of LA fibrosis
404 using previously described protocols (13). Scans were performed on Philips Ingenia and Siemens
405 Avanto clinical scanners, 15 to 25 minutes after contrast injection, using a 3-dimensional
406 inversion-recovery, respiration-navigated, ECG-gated, gradient echo pulse sequence. Acquisition
407 parameters included transverse imaging volume with a voxel size of 1.25 x 1.25 x 2.5 mm

408 (reconstructed to 0.625 x 0.625 x 1.25 mm). Scan time was 5-10 minutes dependent on respiration
409 and heart rate. Fat saturation sequences were used to suppress signal from fatty tissue.

410 **Reconstruction of 3D patient-derived atrial models from LGE-MRI**

411 Geometric models were reconstructed from LGE-MRI and the relative extent of fibrosis in
412 the LA was quantified via an adaptive histogram thresholding algorithm (27). Clinical-grade
413 meshes (i.e., coarse discretization) produced by Merisight Inc. (Salt Lake City, UT) were
414 resampled with a target resolution of 200 μm using an automated process based on gmsh (28).
415 Each LA model was represented as a bilayer comprising of nested endocardial and epicardial
416 shells (21), linked at every point by linear connections ($\sigma = 0.8$ S m^{-1}) (**Fig. 1A**). LA bilayer models
417 were generated by slightly inflating the single-surface mesh to form the epicardial surface (i.e.,
418 duplicating endocardial points then moving them outward by 100 μm along the surface normal
419 vector), then connecting the nested shells by attaching linear elements between corresponding
420 nodes. In each patient-derived model, realistic myocardial fiber orientations were mapped from
421 an atlas geometry (21) using the universal atrial coordinates (UAC) approach. Briefly, this process
422 assigned epicardial and endocardial fibers from a previously published bilayer model to the target
423 atrial geometry (**Fig. 1B**) (29, 30). In all finite element LA meshes, the average element edge
424 length was ≈188 μm and the number of nodes ranged from ≈600,000 to ≈1.4 million, depending
425 on LA size. This mesh resolution is consistent with previously established benchmarks for
426 minimizing numerical error due to spatial discretization in simulations of cardiac wavefront
427 propagation (31, 32).

428 **Modeling of atrial electrophysiology in fibrotic and non-fibrotic regions**

429 Our methodology for computational modeling at the cell and tissue scale of the fibrotic and
430 non-fibrotic atrial electrophysiology can be found in previously published papers (5, 16, 33).
431 Briefly, in non-fibrotic regions, a human atrial action potential model (34) was used to represent
432 membrane kinetics, including parameter modifications to fit clinical monophasic action potential
433 recordings from AFib patients (I_{Kur}, I_{to}, I_{CaL} decreased by 50%, 50%, 70%, respectively) (5, 35). At

434 the tissue scale, conductivity tensor values in non-fibrotic tissue (longitudinal: $\sigma_L = 0.409$ S m^{-1};
435 transverse: $\sigma_T = 0.0820$ S m^{-1}) were calibrated to obtain effective conduction velocity (CV) values
436 of 71.49 cm s^{-1} and 37.14 cm s^{-1} (longitudinal and transverse). These conductivities were chosen
437 as a compromise between CV values measured in patients induced AFib (61±6 cm s^{-1}) (36),
438 clinically mapped patients with AFib or atrial flutter (median: 60 cm s^{-1}; inter-quartile range: 22 cm
439 s^{-1}) (37), and simulations calibrated to match intracardiac mapping data from an individual with
440 paroxysmal AFib (median: 143 cm s^{-1} longitudinal, 94 cm s^{-1} transverse) (38). In fibrotic regions,
441 modifications to the AFib-like action potential model (I_{CaL}, I_{Na}, and I_{K1} decreased by 50%, 40%,
442 50%, respectively) were implemented as in prior studies (5, 39), resulting in a 15.4% increase in
443 action potential duration and a 49.6% decrease in upstroke velocity. These changes represented
444 the effect of elevated transforming growth factor-β1, a key component of the fibrogenic signaling
445 pathway. As in previous studies (5, 16, 33), tissue-scale effects of interstitial fibrosis and gap
446 junction remodeling were represented by reducing overall conductivity and exaggerating the
447 anisotropy ratio (σ_L:σ_T) from 5:1 to 8:1 ($\sigma_L = 0.177$ S m^{-1}; $\sigma_T = 0.0221$ S m^{-1}).

448 **Simulation of electrical activity and numerical aspects**

449 Electrical propagation in bilayer LA models was simulated by solving the monodomain
450 equation using the finite element method. This system was coupled with ordinary differential and
451 algebraic equations representing myocyte membrane dynamics at each node in the mesh, as
452 described in the prior section. All simulations were executed on the Hyak supercomputer system
453 at the University of Washington using the openCARP software package (40, 41), which is
454 available for academic use (see: https://openCarp.org). The compute time required to complete
455 each unique simulation ranged from 1-10 hours. The total CPU time for all simulations conducted
456 in all models was 13.4 years.

457 **Induction and analysis of reentrant atrial arrhythmias**

458 Simulations were performed to assess the pro-arrhythmic propensity of the fibrotic
459 substrate in each patient-derived model. Arrhythmia induction via rapid pacing was attempted

460 from 15 pacing sites derived from AFib trigger sites (**Fig. 1C**, see caption for detailed anatomical
461 site descriptions) (14). Clinically relevant AFib trigger sites were chosen over a random pacing
462 schematic to specifically capture RDs that arise from locations demonstrated to induce AFib. As
463 in previous publications, a clinically relevant pacing sequence of 12 electrical stimuli was delivered
464 at each of the 15 locations (5, 39). Individual cell-scale ionic models were paced to limit cycle at
465 a rate basic cycle length of 500 ms. The electrical stimulus consisted of two initial pulses with a
466 coupling interval of 300ms, followed by pulses ramping down to 200ms in 20ms intervals. After
467 the delivery of the final stimulus, simulations were monitored for self-sustaining electrical
468 wavefront propagation. For all cases in which activity persisted for at least 5,000ms post-pacing,
469 we applied further analysis to determine whether the cause was an induced RD or macroscopic
470 re-entry (i.e., continuous repetitive, self-sustaining activation propagating around a non-
471 conductive obstacle such as the mitral valve or pulmonary vein(s)), which we consider flutter-like
472 reentry. Instances of macroscopic re-entry were excluded from further analysis.

473 For each AFib-inducible simulation, we documented whether each pacing site induced
474 reentry and analyzed patterns of RD localization. Unique RD morphologies in each patient-
475 derived model were classified as belonging to one of five anatomical regions (**Fig. 1D**), which
476 were delineated automatically in a two-step process summarized in **Supplemental Fig. 1**. First,
477 the LA was subdivided into three broad anatomical areas (region 1: LA floor, 2: posterior wall; 3:
478 anterior wall including LAA) using standardized cutoff values in the UAC space (29). Second, the
479 left and right PV areas (regions 4 and 5, respectively) were established using a region-growing
480 approach such that each accounted for 15% of the total LA surface area. We then defined region-
481 wise inducibility scores (IdS) across all models in a particular group (ESUS or AFib) as the
482 proportion of pacing sites within a given region from which rapid pacing resulted in initiation of an
483 RD. For example, since the LPV region contains four pacing sites (anterior/posterior LSPV/LIPV),
484 the corresponding ESUS IdS value would be derived by summing the number of instances in
485 which pacing from those locations induced RD across inducible ESUS models then dividing by

four. This ensured our ability to assess spatial heterogeneity of sensitivity to triggered activity in a manner that was unbiased to the relative abundance of pacing sites in some LA regions.

Quantitative analysis of fibrosis spatial pattern and potentially pro-ectopic effects of fibrosis

Fibrotic tissue areas with both high local fibrosis density (FD) and high local fibrosis entropy (FE) have increased propensity for RD localization, as shown in computational models (15) and intracardiac mapping of patients with persistent AFib (17). We used a constraint equation derived by support vector machine-based classification to delineate such pro-RD regions. As in prior studies (5, 23), the classification polynomial was: $0.4096\ FD^2 + 3.28(FD)(FE) - 0.1036\ FE^2 - 0.7112(FD) - FE + 0.0429$. Maps of pro-RD tissue were subdivided into the five LA regions, as described above and region-specific burdens of pro-RD fibrosis pattern were calculated.

In some situations, fibrosis itself can develop the capacity to generate ectopic triggers of arrhythmia (7, 8). Although the cell-scale models used in this study do not undergo early or delayed afterdepolarizations due to simplified intracellular calcium handling, fibrotic regions in our models do have a potentially pro-ectopic higher resting membrane voltage (V_m) compared to non-fibrotic regions due to reduced ion channel expression levels (I_{CaL}, I_{Na}, I_{K1}). Thus, as a surrogate measure of potential intrinsic pro-trigger capacity in fibrotic tissue, we characterized the extent of tissue in ESUS and AFib models in which the fibrosis pattern resulted in abnormal depolarization. To do this, we allowed all 90 models to reach a quasi-equilibrium state (1000 ms in the absence of pacing). We aggregated resting V_m values across all models and identified the 95th percentile as the threshold for delineation of fibrosis-induced abnormal depolarization (–75.3 mV). Then, we calculated the proportion of tissue in each model with an equilibrium V_m above that threshold.

Statistical Analysis

LA models for ESUS and AFib patients were divided into quartiles based on the extent of fibrotic remodeling as measured by LGE-MRI. Continuous variables were compared pairwise between groups using Wilcoxon rank-sum tests and were reported as mean ± standard deviation.

Confidence intervals were calculated as the interval for the true difference in mean with 95% certainty. Categorical variables were compared using a χ^2 test. After classifying unique RDs and number of pacing sites that induced reentry, correlation with fibrosis was assessed with logistic regression. Statistical significance was established at two-tailed $P \leq 0.05$. All statistical analysis was performed using R (42).

Impact statement: This study uses MRI-based computational modelling to explore why some stroke patients never have arrhythmias, even though they have cardiac fibrosis that strongly associated with arrhythmia risk in other cohorts.

Author contributions: Savannah Bifulco: Conceptualization; Formal analysis; Validation; Investigation; Visualization; Methodology; Writing - original draft; Writing - review and editing Griffin Scott: Formal analysis; Validation; Writing - review and editing Sakher Sarairah: Data curation; Formal analysis; Validation; Visualization; Writing - review and editing Zeinab Birjandian: Data curation; Formal analysis; Validation; Visualization; Writing – review and editing Caroline Roney: Software; Validation; Methodology; Writing - review and editing Steven Niederer: Software; Methodology; Writing - review and editing Christian Mahnkopf: Formal analysis; Validation; Investigation; Writing - review and editing Marcel Mitlacher: Formal analysis; Validation; Investigation; Writing - review and editing Peter Kuhnlein: Formal analysis; Validation; Investigation; Writing - review and editing David Tirschwell: Formal analysis; Validation; Investigation; Writing - review and editing Will Longstreth: Formal analysis; Validation; Investigation; Writing - review and editing Nazem Akoum: Conceptualization; Resources; Data curation; Supervision; Investigation; Writing - original draft; Project administration; Writing - review and editing Patrick Boyle: Conceptualization; Resources; Data curation; Software; Formal analysis; Supervision; Funding acquisition; Validation; Investigation; Visualization; Methodology; Writing - original draft; Project administration; Writing - review and editing.

Acknowledgments: We would like to thank Dr. Colleen Clancy, Dr. Axel Loewe, and our anonymous peer reviewer for extremely helpful and constructive feedback on our manuscript.

Funding: ARCS Foundation: Savannah F Bifulco; UKRI | Medical Research Council (MRC): Caroline H Roney, MR/S015086/1; National Institutes of Health: Steven A Niederer, R01-HL152256; European Research Council: Steven A Niederer, PREDICT-HF (864055); British Heart Foundation (BHF): Steven A Niederer, RG/20/4/34803; UKRI | Engineering and Physical Sciences Research Council (EPSRC): Steven A Niederer, EP/P01268X/1; Wellcome Trust: Steven A Niederer, 203148/Z/16/Z; HHS | National Institutes of Health (NIH): David Tirschwell, Will T Longstreth, NIH 5-U01-NS095869; John Locke Charitable Trust: Nazem Akoum The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Data availability: Where possible (**Figs. 2, 3, 5, and 6**), raw numerical data underlying figures are available via figshare [to be linked]. Patient-derived data related to this article will be shared with interested parties for non-commercial reuse on reasonable request to the co-corresponding authors and approval from the Institutional Review Board of the University of Washington.

Ethics: Human Subjects: Yes. Ethics Statement: This study was approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland; all participants provided written informed consent. Clinical Trial: No. Animal Subjects: No.

References

1. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114(9):1453-68.

558 2. Israel C, Kitsiou A, Kalyani M, Deelawar S, Ejangue LE, Rogalewski A, et al. Detection
559 of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged
560 monitoring with implantable loop recorders. Thromb Haemost. 2017;117(10):1962-9.

561 3. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al.
562 Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients:
563 Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. Circ
564 Arrhythm Electrophysiol. 2016;9(1):e003333.

565 4. Tandon K, Tirschwell D, Longstreth WT, Jr., Smith B, Akoum N. Embolic stroke of
566 undetermined source correlates to atrial fibrosis without atrial fibrillation. Neurology.
567 2019;93(4):e381-e7.

568 5. Zahid S, Cochet H, Boyle PM, Schwarz EL, Whyte KN, Vigmond EJ, et al. Patient-
569 derived models link re-entrant driver localization in atrial fibrillation to fibrosis spatial pattern.
570 Cardiovasc Res. 2016;110(3):443-54.

571 6. Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, et al. Computationally
572 guided personalized targeted ablation of persistent atrial fibrillation. Nat Biomed Eng.
573 2019;3(11):870-9.

574 7. Gouvea de Barros B, Weber dos Santos R, Lobosco M, Alonso S. Simulation of Ectopic
575 Pacemakers in the Heart: Multiple Ectopic Beats Generated by Reentry inside Fibrotic Regions.
576 Biomed Res Int. 2015;2015:713058.

577 8. Alonso S, Dos Santos RW, Bar M. Reentry and Ectopic Pacemakers Emerge in a Three-
578 Dimensional Model for a Slab of Cardiac Tissue with Diffuse Microfibrosis near the Percolation
579 Threshold. PLoS One. 2016;11(11):e0166972.

580 9. Roney CH, Beach ML, Mehta A, Sim I, Corrado C, Bendikas R, et al. In silico
581 comparison of left atrial ablation techniques that target the anatomical, structural and electrical
582 substrates of atrial fibrillation. Front Physiol. 2020.

583 10. Xia Y, Hertervig E, Kongstad O, Ljungstrom E, Platonov P, Holm M, et al. Deterioration
584 of interatrial conduction in patients with paroxysmal atrial fibrillation: electroanatomic mapping of
585 the right atrium and coronary sinus. Heart Rhythm. 2004;1(5):548-53.

586 11. Litchenberg WH, Norman LW, Holwell AK, Martin KL, Hewett KW, Gourdie RG. The rate
587 and anisotropy of impulse propagation in the postnatal terminal crest are correlated with
588 remodeling of Cx43 gap junction pattern. Cardiovasc Res. 2000;45(2):379-87.

589 12. Hakim JB, Murphy MJ, Trayanova NA, Boyle PM. Arrhythmia dynamics in computational
590 models of the atria following virtual ablation of re-entrant drivers. Europace.
591 2018;20(suppl_3):iii45-iii54.

592 13. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association
593 of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter
594 ablation: the DECAAF study. JAMA. 2014;311(5):498-506.

595 14. Santangeli P, Marchlinski FE. Techniques for the provocation, localization, and ablation
596 of non-pulmonary vein triggers for atrial fibrillation. Heart Rhythm. 2017;14(7):1087-96.

597 15. Roney CH, Bayer JD, Zahid S, Meo M, Boyle PM, Trayanova NA, et al. Modelling
598 methodology of atrial fibrosis affects rotor dynamics and electrograms. Europace. 2016;18(suppl
599 4):iv146-iv55.

600 16. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Vigmond EJ, et al.
601 Comparing Reentrant Drivers Predicted by Image-Based Computational Modeling and Mapped
602 by Electrocardiographic Imaging in Persistent Atrial Fibrillation. Front Physiol. 2018;9:414.

603 17. Cochet H, Dubois R, Yamashita S, Al Jefairi N, Berte B, Sellal JM, et al. Relationship
604 Between Fibrosis Detected on Late Gadolinium-Enhanced Cardiac Magnetic Resonance and
605 Re-Entrant Activity Assessed With Electrocardiographic Imaging in Human Persistent Atrial
606 Fibrillation. JACC Clin Electrophysiol. 2018;4(1):17-29.

607 18. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, et al. Driver
608 domains in persistent atrial fibrillation. Circulation. 2014;130(7):530-8.

609 19. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, et al. Spatial
610 distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart
611 failure. Circ Res. 2007;101(8):839-47.

612 20. Deng D, Murphy MJ, Hakim JB, Franceschi WH, Zahid S, Pashakhanloo F, et al.
613 Sensitivity of reentrant driver localization to electrophysiological parameter variability in image-
614 based computational models of persistent atrial fibrillation sustained by a fibrotic substrate.
615 Chaos. 2017;27(9):093932.

616 21. Labarthe S, Bayer J, Coudiere Y, Henry J, Cochet H, Jais P, et al. A bilayer model of
617 human atria: mathematical background, construction, and assessment. Europace. 2014;16
618 Suppl 4:iv21-iv9.

619 22. Hansen BJ, Zhao J, Li N, Zolotarev A, Zakharkin S, Wang Y, et al. Human Atrial
620 Fibrillation Drivers Resolved With Integrated Functional and Structural Imaging to Benefit
621 Clinical Mapping. JACC Clin Electrophysiol. 2018;4(12):1501-15.

622 23. Ali RL, Hakim JB, Boyle PM, Zahid S, Sivasambu B, Marine JE, et al. Arrhythmogenic
623 propensity of the fibrotic substrate after atrial fibrillation ablation: a longitudinal study using
624 magnetic resonance imaging-based atrial models. Cardiovasc Res. 2019;115(12):1757-65.

625 24. Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, et al. Preprocedure
626 Application of Machine Learning and Mechanistic Simulations Predicts Likelihood of Paroxysmal
627 Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation. Circ Arrhythm Electrophysiol.
628 2020;13(7):e008213.

629 25. Boyle PM, Del Alamo JC, Akoum N. Fibrosis, atrial fibrillation and stroke: clinical updates
630 and emerging mechanistic models. Heart. 2021;107(2):99-105.

631 26. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic Stroke of
632 Undetermined Source: A Systematic Review and Clinical Update. Stroke. 2017;48(4):867-72.

633 27. Jadidi AS, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, et al. Inverse relationship
634 between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined
635 magnetic resonance imaging and high-density mapping. J Am Coll Cardiol. 2013;62(9):802-12.

636 28. Geuzaine C, Remacle J-F. Gmsh: A 3-D finite element mesh generator with built-in pre-
637 and post-processing facilities. International Journal for Numerical Methods in Engineering.
638 2009;79(11):1309-31.

639 29. Roney CH, Pashaei A, Meo M, Dubois R, Boyle PM, Trayanova NA, et al. Universal
640 atrial coordinates applied to visualisation, registration and construction of patient specific
641 meshes. Med Image Anal. 2019;55:65-75.

642 30. Roney CH, Bendikas R, Pashakhanloo F, Corrado C, Vigmond EJ, McVeigh ER, et al.
643 Constructing a Human Atrial Fibre Atlas. Ann Biomed Eng. 2020.

644 31. Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, et al.
645 Verification of cardiac tissue electrophysiology simulators using an N-version benchmark. Philos
646 Trans A Math Phys Eng Sci. 2011;369(1954):4331-51.

647 32. Boyle PM, Ochs AR, Ali RL, Paliwal N, Trayanova NA. Characterizing the
648 arrhythmogenic substrate in personalized models of atrial fibrillation: sensitivity to mesh
649 resolution and pacing protocol in AF models. Europace. 2021;23(suppl_1):i3-i11.

650 33. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Prakosa A, et al. The
651 Fibrotic Substrate in Persistent Atrial Fibrillation Patients: Comparison Between Predictions
652 From Computational Modeling and Measurements From Focal Impulse and Rotor Mapping.
653 Front Physiol. 2018;9:1151.

654 34. Courtemanche M, Ramirez RJ, Nattel S. Ionic mechanisms underlying human atrial
655 action potential properties: insights from a mathematical model. Am J Physiol.
656 1998;275(1):H301-21.

657 35. Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, et al. Mechanisms of
658 human atrial fibrillation initiation: clinical and computational studies of repolarization restitution
659 and activation latency. Circ Arrhythm Electrophysiol. 2012;5(6):1149-59.

660 36. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High-density
661 mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89(4):1665-80.

662 37. Verma B, Oesterlein T, Loewe A, Luik A, Schmitt C, Dossel O. Regional conduction
663 velocity calculation from clinical multichannel electrograms in human atria. Comput Biol Med.
664 2018;92:188-96.

665 38. Roney CH, Whitaker J, Sim I, O'Neill L, Mukherjee RK, Razeghi O, et al. A technique for
666 measuring anisotropy in atrial conduction to estimate conduction velocity and atrial fibre
667 direction. Comput Biol Med. 2019;104:278-90.

668 39. Zahid S, Whyte KN, Schwarz EL, Blake RC, 3rd, Boyle PM, Chrispin J, et al. Feasibility
669 of using patient-specific models and the "minimum cut" algorithm to predict optimal ablation
670 targets for left atrial flutter. Heart Rhythm. 2016;13(8):1687-98.

671 40. Vigmond EJ, Hughes M, Plank G, Leon LJ. Computational tools for modeling electrical
672 activity in cardiac tissue. J Electrocardiol. 2003;36 Suppl:69-74.

673 41. Vigmond EJ, Weber dos Santos R, Prassl AJ, Deo M, Plank G. Solvers for the cardiac
674 bidomain equations. Prog Biophys Mol Biol. 2008;96(1-3):3-18.

675 42. R Development Core Team. R: A language and environment for statistical computing.
676 Vienna, Austria: R Fonudation for Statistical Computing; 2019.
677

678

679

Supplemental Information



Supplemental Figure 1. LA subdivision scheme. (A) Alpha coordinate from universal atrial coordinate (UAC) system mapped on to a representative LA model. (B) Beta coordinate from UAC mapped on to a representative LA model. (C) 2D representation of UAC with pulmonary vein locations labeled. Dashed lines represent edges of the five atrial regions. (D) Segmented LA mapped onto a 3D mesh with numbered regions corresponding to regions in (C). (E) Final division scheme after edge expansion of the LPVs and RPVs to generate regions 3 and 4, respectively.



Supplemental Figure 2. Boxplot depicting the percentage of tissue with significantly depolarized tissue (>95th percentile) between ESUS and AFib models after reaching steady state. P=0.32; CI: [–0.007, 0.019].